Entera BioENTX -6.45%23 PB Ratio is 6.33 as of Jun. 25, 2026, which is 42% above its 10-year median of 4.47. GuruFocus rates ENTX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,233 Biotechnology companies, Entera Bio ranks worse than 78.1% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Entera Bio's share price is $1.45. Entera Bio's Book Value per Share for the quarter that ended in Mar. 2026 was $0.23. Hence, Entera Bio's PB Ratio of today is 6.33.
The historical rank and industry rank for Entera Bio's PB Ratio or its related term are showing as below:
ENTX'
s PB Ratio Range Over the Past 10 Years
Min: 1.01 Med: 4.47 Max: 19.33
Current: 6.3
During the past 11 years, Entera Bio's highest PB Ratio was 19.33. The lowest was 1.01. And the median was 4.47.
ENTX's PB Ratio is ranked worse than 78.1% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs ENTX: 6.30
During the past 12 months, Entera Bio's average Book Value Per Share Growth Rate was -46.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -11.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -14.40% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Entera Bio was -3.90% per year. The lowest was -35.70% per year. And the median was -11.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Entera Bio PB Ratio Related Terms
Entera Bio PB Ratio Historical Data
* Premium members only.
The historical data trend for Entera Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entera Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Entera Bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Entera Bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Entera Bio (ENTX) has a PB Ratio of 6.33 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Entera Bio and its competitors. This is 42% above median its historical median of 4.47. Over the past decade, Entera Bio's PB Ratio has ranged from 1.01 to 19.33. According to the industry distribution chart, Entera Bio ranks #963 out of 1233 companies in the Biotechnology industry, placing it in the top 78.1%.
Is Entera Bio's PB Ratio too high?
Entera Bio's current PB Ratio of 6.33 is 42% above median its 10-year median of 4.47. Over the past 10 years, this metric has ranged from a low of 1.01 to a high of 19.33. The Biotechnology industry median PB Ratio is 2.80. Entera Bio's value of 6.33 is 126.1% above this industry median. Based on the distribution chart, Entera Bio ranks #963 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Entera Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's PB Ratio compare to IMA and MNOV?
According to the Biotechnology industry distribution chart, Entera Bio ranks #963 out of 1233 companies for PB Ratio. This places Entera Bio in the lower half of its industry. The industry median PB Ratio is 2.80. Entera Bio's value of 6.33 is 126.1% above this benchmark. Historically, Entera Bio's own PB Ratio has ranged from 1.01 to 19.33 over the past decade. While the company's 10-year median is 4.47 vs. the industry median of 2.80, Entera Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entera Bio's current PB Ratio of 6.33 is 126.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Entera Bio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entera Bio's current PB Ratio is 6.33, which is 42% above median its own 10-year median of 4.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (ENTX) has a current PB Ratio of 6.33. The current PB Ratio is 6.33, which is 42% above median its 10-year median of 4.47 and 126.1% above the Biotechnology industry median of 2.80. Entera Bio's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Entera Bio (ENTX), the current PB Ratio is 6.33 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
23GF Score
Get the complete analysis for ENTX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENTX has been successfully added to your 
